229 related articles for article (PubMed ID: 34750506)
21. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
Rocnik JL; Okabe R; Yu JC; Lee BH; Giese N; Schenkein DP; Gilliland DG
Blood; 2006 Aug; 108(4):1339-45. PubMed ID: 16627759
[TBL] [Abstract][Full Text] [Related]
22. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
Larrue C; Saland E; Boutzen H; Vergez F; David M; Joffre C; Hospital MA; Tamburini J; Delabesse E; Manenti S; Sarry JE; Récher C
Blood; 2016 Feb; 127(7):882-92. PubMed ID: 26286850
[TBL] [Abstract][Full Text] [Related]
23. Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication.
Natarajan K; Xie Y; Burcu M; Linn DE; Qiu Y; Baer MR
PLoS One; 2013; 8(9):e74653. PubMed ID: 24040307
[TBL] [Abstract][Full Text] [Related]
24. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
Wu M; Li L; Hamaker M; Small D; Duffield AS
Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
[TBL] [Abstract][Full Text] [Related]
25. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib
Dumas PY; Naudin C; Martin-Lannerée S; Izac B; Casetti L; Mansier O; Rousseau B; Artus A; Dufossée M; Giese A; Dubus P; Pigneux A; Praloran V; Bidet A; Villacreces A; Guitart A; Milpied N; Kosmider O; Vigon I; Desplat V; Dusanter-Fourt I; Pasquet JM
Haematologica; 2019 Oct; 104(10):2017-2027. PubMed ID: 30923103
[TBL] [Abstract][Full Text] [Related]
26. Nuclear factor of activated T-cells, NFATC1, governs FLT3
Solovey M; Wang Y; Michel C; Metzeler KH; Herold T; Göthert JR; Ellenrieder V; Hessmann E; Gattenlöhner S; Neubauer A; Pavlinic D; Benes V; Rupp O; Burchert A
J Hematol Oncol; 2019 Jul; 12(1):72. PubMed ID: 31286998
[TBL] [Abstract][Full Text] [Related]
27. The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia.
Cao T; Jiang N; Liao H; Shuai X; Su J; Zheng Q
Sci Rep; 2019 Aug; 9(1):12209. PubMed ID: 31434952
[TBL] [Abstract][Full Text] [Related]
28. FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation.
Oellerich T; Mohr S; Corso J; Beck J; Döbele C; Braun H; Cremer A; Münch S; Wicht J; Oellerich MF; Bug G; Bohnenberger H; Perske C; Schütz E; Urlaub H; Serve H
Blood; 2015 Mar; 125(12):1936-47. PubMed ID: 25605370
[TBL] [Abstract][Full Text] [Related]
29. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G
J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456
[TBL] [Abstract][Full Text] [Related]
30. FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.
Kim HG; Kojima K; Swindle CS; Cotta CV; Huo Y; Reddy V; Klug CA
Blood; 2008 Feb; 111(3):1567-74. PubMed ID: 17967943
[TBL] [Abstract][Full Text] [Related]
31. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
[TBL] [Abstract][Full Text] [Related]
32. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase.
Yang X; Sexauer A; Levis M
Br J Haematol; 2014 Jan; 164(1):61-72. PubMed ID: 24116827
[TBL] [Abstract][Full Text] [Related]
33. circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression.
Sun YM; Wang WT; Zeng ZC; Chen TQ; Han C; Pan Q; Huang W; Fang K; Sun LY; Zhou YF; Luo XQ; Luo C; Du X; Chen YQ
Blood; 2019 Oct; 134(18):1533-1546. PubMed ID: 31387917
[TBL] [Abstract][Full Text] [Related]
34. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
Elife; 2016 Nov; 5():. PubMed ID: 27879203
[TBL] [Abstract][Full Text] [Related]
35. Targeting RIPK1 in AML cells carrying FLT3-ITD.
Hillert LK; Bettermann-Bethge K; Nimmagadda SC; Fischer T; Naumann M; Lavrik IN
Int J Cancer; 2019 Sep; 145(6):1558-1569. PubMed ID: 30828789
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic FLT3 internal tandem duplication activates E2F1 to regulate purine metabolism in acute myeloid leukaemia.
Ou ZY; Wang K; Shen WW; Deng G; Xu YY; Wang LF; Zai ZY; Ling YA; Zhang T; Peng XQ; Chen FH
Biochem Pharmacol; 2023 Apr; 210():115458. PubMed ID: 36803956
[TBL] [Abstract][Full Text] [Related]
37. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.
Köthe S; Müller JP; Böhmer SA; Tschongov T; Fricke M; Koch S; Thiede C; Requardt RP; Rubio I; Böhmer FD
J Cell Sci; 2013 Oct; 126(Pt 20):4746-55. PubMed ID: 23943874
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress.
Akiyama H; Umezawa Y; Ishida S; Okada K; Nogami A; Miura O
Cancer Lett; 2019 Jul; 453():84-94. PubMed ID: 30946869
[TBL] [Abstract][Full Text] [Related]
39. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
40. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
